Breast

Preventing Breast Cancer Just Got Easier. Will More Women Give These Drugs A Try?

(Los Angeles Times) Jan 15, 2019 - Breast cancer will strike 1 in 8 women in her lifetime. But women who face an increased risk of being that one unlucky patient may improve their chances with three prescription medications, according to a new report. If 1,000 women took one of the three medications for roughly five years, somewhere between seven and 18 breast cancers could be prevented, and possibly more. But each of the drugs — two originally used to treat breast cancer and a third that prevents the bone-thinning disease osteoporosis — comes with the possibility of serious side effects, including blood clots and a higher likelihood of uterine or endometrial cancer. That mixed picture prompted a panel of preventive healthcare experts to suggest that doctors routinely discuss these medications with women who have an elevated risk of breast cancer.

read article (free registration required)

New Tool Calculates Breast Cancer Risk With Greater Precision

(CNN) Jan 15, 2019 - UK scientists have developed an online calculator that could enable doctors to more accurately predict a patient's chance of developing breast cancer. Among other things, details of family history, genetics, weight, alcohol consumption, age at menopause and use of hormone replacement therapy will all be considered by doctors when assessing a woman's risk of developing breast cancer -- the most common form of cancer in the UK.

read article

New Breast Cancer Testing Tool In Development

(PharmaTimes [UK]) Jan 16, 2019 - A study carried out by researchers from the University of Cambridge, National Cancer Institute, National Institutes of Health in the US among others has shown how putting different genetic and risk factor data into a prediction equation could help us understand how likely a woman is to develop breast cancer. The breast cancer prediction model - called the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm, or “BOADICEA” - is a highly complex equation that takes into account risk factors for breast cancer such as obesity and alcohol intake, plus genetic data and mammography findings. "This is the first time that anyone has combined so many elements into one breast cancer prediction tool," said Prof Antonis Antoniou, lead researcher at the University of Cambridge.

read article

USPSTF Reaffirms Drugs for Women at High Risk for Breast Cancer

(Medscape Medical News ) Jan 15, 2019 - In a new draft recommendation, the US Preventive Services Task Force (USPSTF) has reaffirmed its support for chemoprevention with tamoxifen (multiple brands) and raloxifene (Evista, Lilly) for women at increased risk for breast cancer and has added aromatase inhibitors (AIs) to its recommendation. The inclusion of AIs is the primary difference between the new draft guidelines and the previous recommendations, issued in 2013. However, only raloxifene and tamoxifen have been approved by the US Food and Drug Administration as chemoprevention for this indication, and raloxifene is only indicated for use in postmenopausal women.

read article (free registration required)

After 37 Years Of Trying, This Biotech Nears A First Drug Approval In Breast Cancer

(STAT Plus) Jan 16, 2019 - Immunomedics was founded in 1982. Thirty-seven years later, the biotech is finally on the cusp of its first marketing approval — possibly ending one of the longest drug-development droughts in the industry’s history.

read article (paid subscription required)

Phoenix Molecular Designs Announces Collaboration To Develop Diagnostic for Triple-Negative Breast Cancer

(BioSpace) Jan 16, 2019 - Phoenix Molecular Designs, a privately-held biotechnology company designing precise cancer therapeutics by targeting essential kinases, announced that it has entered into a collaboration with Roche to develop a diagnostic (CDx) in triple-negative breast cancer (TNBC).

read article

FDA Action Alert: Exelixis and Immunomedics

(BioSpace) Jan 14, 2019 - Because of the government shutdown, which as of Monday, January 14 is into its fourth week, 40 percent of the U.S. Food and Drug Administration (FDA) employees were furloughed. There’s been a fair amount of media attention paid to how this affects routine food inspections—they weren’t being performed—but less attention was paid to how it affected drug approvals. The agency is continuing to carry out reviews funded by fiscal year (FY) 2018 Prescription Drug User Fee Act user fees, so the two approvals described here should still be on track. However, the FDA is not currently accepting FY 2019 user fees until the government gets back to work.

read article

In Breast-Cancer Prevention, Race Matters

(Ohio State University) Jan 14, 2019 - African-American women at high risk of breast cancer are less likely than white women to pursue potentially life-saving preventive care, and racial disparities in health care and elsewhere are to blame, new research suggests.

read article

Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer

(The Business Journals) Jan 14, 2019 - Daiichi Sankyo Company, Limited announced that the first patient has been dosed in DESTINY-Breast04, a global pivotal phase 3 study evaluating the safety and efficacy of [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate (ADC), in patients with HER2 low, unresectable and/or metastatic breast cancer previously treated with standard chemotherapy.

read article

Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada

(MarketWatch) Jan 11, 2019 - Puma Biotechnology, Inc., a biopharmaceutical company, announced that it has entered into an exclusive License Agreement with Knight Therapeutics Inc. that grants Knight the exclusive right to commercialize NERLYNX® (neratinib) in Canada.

read article

Novartis Defends Itself Against Kickback Allegations From Former Employee

(BioSpace) Jan 10, 2019 - Swiss pharma giant Novartis has found itself at the center of a legal battle that could determine if the company engaged in a research project that was a kickback in disguise.

read article

CNIO Researchers Confirm Links Between Aggressive Prostate Cancer And Hereditary Breast Cancer

(CNIO [Madrid, Spain]) Jan 9, 2019 - Aggressive prostate cancer, one of the leading causes of cancer deaths in men, is associated with BRCA2 mutations, which are also linked to hereditary breast cancer, ovarian cancer and pancreas cancer, among others. The finding was confirmed in a study, published in the Journal of Clinical Oncology, led by Elena Castro, Nuria Romero-Laorden and David Olmos, from the Prostate Cancer Clinical Research Unit at the Spanish National Cancer Research Centre (CNIO). It reveals that family members of patients with prostate cancer who carry BRCA2 and DNA-repair gene mutations have an increased risk of developing cancer and should be evaluated in familial cancer prevention programmes. Furthermore, the new study shows that prostate cancer in men with BRCA2 mutations is associated with worse outcomes and poor responses to standard treatments. Researchers are currently assessing the benefits of ovarian and breast cancer therapies for prostate cancer patients.

read article

5,000 Women Needed: Study About Breast Cancer Screening Seeks New Jersey Women

(USA Today/North Jersey Record) Jan 9, 2019 - The state’s largest health insurer is recruiting women it insures to participate in a nationwide study about how frequently women should be screened for breast cancer — whether annual mammograms or a personalized schedule based on risk factors is best. Horizon Blue Cross Blue Shield of New Jersey announced Tuesday that it would cover the costs for 5,000 women to join the study, which is being conducted by researchers with the University of California medical centers and a Midwestern health system. Clinical guidelines and experts differ on when women should start to have regular mammograms and how frequently they should do so. The WISDOM study — a creative acronym for Women Informed to Screen Depending on Measures of Risk — aims to improve care by studying the experiences of 100,000 women for five years.

read article

WANTED: Five Thousand Horizon BCBSNJ Members for National Study to Improve Breast Cancer Screening

(Horizon BCBSNJ) Jan 8, 2019 - Breast cancer experts offer differing advice when it comes to when and how often a woman should get a mammogram and that conflicting advice has created confusion that could have an impact on treatment. Horizon Blue Cross Blue Shield of New Jersey (Horizon BCBSNJ) is addressing this problem by covering the cost for 5,000 of its members to participate in a five-year study intended to improve screening guidelines. The Women Informed to Screen Depending On Measures of Risk (WISDOM) Study seeks to clarify which method is safer and more effective for women: routine yearly screening or a personalized screening schedule that takes into consideration genetic and other personal factors like age, family history, and breast density.

read press release

BRCA Exchange Aggregates Data On Thousands Of BRCA Variants To Inform Understanding Of Cancer Risk

(NCI) Jan 9, 2019 - A global resource that includes data on thousands of inherited variants in the BRCA1 and BRCA2 genes is available to the public.

read press release

Athenex Announces Completion of Target Enrollment in the Oraxol Phase III Study

(NASDAQ) Jan 9, 2019 - Top line data from the study is expected to be available in mid-2019.

read article

As Surgeons Tout Robot-Assisted Breast Cancer Surgeries, Safety Remains A Question

(Columbus Dispatch/Philadelphia Inquirer) Jan 6, 2019 - Now, robot-assisted surgery — the most high-tech, high-cost version of minimally invasive technology — is being introduced for breast cancer treatment. But rigorous clinical trials have not been done to compare the safety of robotic approaches with conventional methods.

read article

SELLAS Life Sciences Provides Update on Late-Stage Immunotherapy Clinical Development Pipeline

(Markets Insider) Jan 8, 2019 - Aligned with FDA on phase 3 registration-enabling trial for galinpepimut-S (GPS) in Acute Myeloid Leukemia; trial expected to start in Q2 2019. Enrollment of phase 1/2 basket trial of GPS plus Keytruda® (pembrolizumab) initiated; interim analysis anticipated in Q4 2019.

read article

Ribon Raises $65M to Pursue PARP-Blocking Pills for Cancer

(Xconomy Boston) Jan 4, 2019 - A new class of ovarian and breast cancer drugs that thwart a DNA repair mechanism ushered in a novel approach to treating cancer.

read article

Evelo Biosciences Announces Dosing of First Patient in Phase 1/2 Clinical Trial of EDP1503 in Combination with KEYTRUDA® (pembrolizumab) in Multiple Oncology Indications

(Yahoo! Finance) Jan 4, 2019 - Evelo Biosciences, Inc. today announced that it has dosed the first patient in its Phase 1/2 clinical trial of EDP1503 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. EDP1503 is an orally delivered monoclonal microbial product candidate being developed for the treatment of cancer.

read article
Next Page